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Purpose: This study was conducted to analyze the feasibility of omitting irradiation to the contralateral lower neck
in stage N1 nasopharyngeal carcinoma (NPC) patients.
Materials and methods: From July 2008 to January 2012, 52 patients with stage N1 NPC were analyzed. All
patients were treated with intensity-modulated radiation therapy (IMRT) and received bilateral upper neck
irradiation to levels II, III and VA and ipsilateral lower neck irradiation to levels IV and VB. The contralateral lower
neck irradiation was omitted.
Results: The median follow-up was 29 months (range, 12–52 months). The 3-year overall survival (OS) rate,
progress-free survival (PFS), local failure-free (LFS), nodal recurrence-free survival (NFS) and distant metastasis-free
survival (DMFS) rates were 92.2%, 94.1%, 94.3%, 98% and 94.1%, respectively. Only one patient developed a neck
recurrence in the irradiation field, while no patients experienced out-of-field nodal recurrence. Univariate analysis
suggested that T classification was the only significant prognostic factor for overall survival, and age was
significantly associated with PFS. Multivariate analyses indicated that age was also a predictor for overall survival.
The elective neck irradiation procedure was not a significant predictor for all of the treatment results.
Conclusion: Selective irradiation to bilateral levels of II, III and VA and unilateral levels of IV and VB, omitted the
contralateral lower neck in a proportion of patients with N1 stage NPC was safe and practicable.
Keywords: Nasopharyngeal carcinoma, Selective irradiation, Cervical lymph node metastasisIntroduction
Nasopharyngeal carcinoma (NPC) is a highly infiltrative
tumor and is prone to cervical lymph node metastasis
because of the rich lymphatic network in the nasophar-
ynx [1-3]. Traditionally, irradiation treatment of the en-
tire cervical lymph nodal drainage region has been
considered a necessity. Some studies proposed that rou-
tine irradiation to the retropharyngeal area, levels II–V
and the supraclavicular lymph nodal areas were needed
regardless of the nodal metastasis status [4,5].
However, based on current technology, clinical data
indicate that elective neck irradiation was relatively safe
and practicable. Tang et al. [6] reported that there was
no statistical difference in risk for regional recurrence* Correspondence: antica@gmail.com
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reproduction in any medium, provided the orand distant metastasis in N0 patients with a cricoid cartil-
age as the inferior border of the neck irradiation field
when compared with those irradiated below the cricoid
cartilage. Gao et al. [7] reported that elective level II, III
and VA irradiation was suitable for NPC without neck
lymph node metastasis. A more recent study reported that
elective irradiation to levels II, III and VA was not inferior
to whole-neck irradiation for NPC patients with retro-
pharyngeal lymph nodes metastasis only [8]. Because no
consensus has been reached on the amount of irradiation
required for the necks of NPC patients, it is reasonable to
question the necessity of irradiation for the bilateral lower
neck lymph node levels, including the inferior area of
levels V and level IV and the supraclavicular regions in
partial N1 patients with only unilateral upper lymph node
involvement in the neck. In this study, we investigated the
probability of disease recurrence in the unilateral lowerThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gions in patients with positive unilateral upper cervical
lymph node and explored the feasibility of reducing the ir-
radiation range in N1 patients.
Materials and methods
Patient selection and pretreatment evaluation
Between July 2008 and January 2012, 52 consecutive pa-
tients were treated with intensity-modulated radiation
therapy (IMRT) at the Cancer Hospital of Fudan Univer-
sity. The inclusion criteria for this study were: (1) histo-
pathologically confirmed squamous cell carcinoma (SCC)
of the nasopharynx; (2) T1-4N1M0 disease (according to
the American Joint Committee on Cancer (AJCC) 7th
staging system); (3) no previous anti-tumor therapy; (4) a
Karnofsky Performance Status (KPS) ≥80; and (5) mag-
netic resonance imaging (MRI) pretreatment of the naso-
pharynx and neck.
Pretreatment evaluations included a complete medical
history, physical examination, indirect or fiberoptic endo-
scopic examination, chest X-ray or computed tomography
(CT), abdominal ultrasound or CT, MRI scans of naso-
pharynx and neck and complete blood counts. Bone scans
were performed on patients with T3–4 disease and symp-
tomatic patients. Patients were staged using the AJCC 7th
staging system. Cervical lymph nodes were considered to
be positive only if the shortest axial diameter of the
jugulodigastric lymph node was ≥11 mm, the shortest
axial diameter of the other lymph nodes was ≥10 mm or
there was a group of three or more lymph nodes of crit-
ical size [9,10]. The lateral retropharyngeal lymph nodes
(RLNs) were defined as metastatic if their shortest
diameter was ≥5 mm. Any visible nodes in the median
RLN were considered to be malignant [11,12], and any
imaging evidence of extracapsular spread or central ne-
crosis was also a sign of metastasis [9-12].
Radiotherapy
All patients were treated with IMRT and immobilized in
the supine position with a thermoplastic mask. CT scans
were obtained from the anterior clinoid process to the
hyoid bone in 3-mm slices and from the hyoid bone to
2 cm below the sternoclavicular joint in 5-mm slices.
The gross tumor volume (GTV) identified on fusion
MRI and CT scans included primary nasopharyngeal tu-
mors (GTVnx) and involved lymph nodes (GTVnd). The
clinical target volume (CTV) contains two parts. The
CTV1 covered the entire nasopharynx, parapharyngeal
space, clivus, skull base, pterygopalatine fossa, posterior
half of the ethmoidal sinus, inferior sphenoid sinus, pos-
terior one-third to one-half of the nasal cavity and max-
illary sinus.
The bilateral upper neck lymph drainage region of levels
II, III and VA was also included as high-risk CTV2;additionally, ipsilateral lower neck lymph node drainage
areas, including levels IV and VB and the supraclavicular
regions, were delineated as a low-risk CTV2. However,
the contralateral lower neck and the supraclavicular
lymph node drainage areas were omitted and excluded as
part of the CTV. More specifically, patients without en-
larged left upper cervical lymph nodes did not accept left
neck lymph node irradiation of levels IV and VB. Con-
versely, patients without enlarged right upper cervical
lymph nodes did not accept right neck lymph node irradi-
ation of levels IV and VB.
The planning target volume (PTV) included CTV to-
gether with a margin of 3–5 mm to overcome both patient
or organ motion and set-up error [13]. The prescribed
doses were 66 Gy for T1-2 disease and 70.4 Gy for T3-4
disease to the PTV in the nasopharynx and 66 Gy for
positive lymph nodes in 30–32 fractions. The prescribed
dose for the upper neck lymph drainage region was 60 Gy,
and the dose range for lower neck lymph node drainage
areas was 54–60 Gy in 30–32 fractions.
The residual disease diagnosed by physical examin-
ation, including MRI, endoscopic examination and clin-
ical examination, was treated with external-beam boost
radiation using IMRT. The boost dose ranged from 6 Gy
to 8 Gy in 3 to 4 fractions.
Chemotherapy
Patients with stage II tumors received concurrent single
agent chemotherapy with cisplatin 80 mg/m2 intravenously
(IV) over 3 days every 3 weeks or 30 mg/m2 weekly. Pa-
tients with stage III and IV tumors received neoadjuvant
chemotherapy with concurrent chemotherapy. Neoadjuvant
chemotherapy mainly consisted of 2–3 cycles of TPF or
TP. The TPF protocol consisted of docetaxel 75 mg/m2 IV
and cisplatin 75 mg/m2 IV over 3 days and 5-fluorouracil
(5-Fu) 2500 mg/m2 continuously IV 120 h. The TP regimen
consisted of docetaxel 75 mg/m2 IV and cisplatin 80 mg/
m2 IV over 3 days. The concurrent chemotherapy regimen
was same as the regimen implemented in patients with
stage II disease.
Follow-up
Patients were followed up for disease status and treatment-
related toxicity every 3 months in the first and second
years, then every 6 months during the next 2–5 years.
Each follow-up included a complete physical examin-
ation, nasopharyngoscopy or indirect nasopharyngeal
speculum examination, serum biochemical profile and
an abdominal ultrasound. Nasopharyngeal MRI was
performed every 6 months. The chest CT and elec-
tronic epipharyngoscope were performed at least once
every year. Bone scans, abdominal CT and PET-CT
were performed when clinically indicated. Late toxic-
ities were evaluated according to the toxicity criteria
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each follow-up [14].Statistical analysis
All analyses were performed using the SPSS software sys-
tem (version 17.0; Chicago, IL). The endpoints included
overall survival (OS), local recurrence-free survival (LFS),
nodal recurrence-free survival (NFS), progression-free sur-
vival (PFS) and distant metastasis-free survival (DMFS).
All endpoints were defined as the interval from the treat-
ment completion date to the date of failure or the last
follow-up date. The Kaplan-Meier method was used to
calculate the probabilities of OS, PFS, LFS, NFS and DFFS
[15], and log-rank test performance was used to compare
the differences [16]. The statistical analyses were two-
sided, and P ≤0.05 was considered to be statistically sig-
nificant. A multifactor Cox model was used to define the
independent prognostic factors.Results
Patients and treatment outcomes
A total of 52 patients with pathologically confirmed
NPC were recruited in this study. The median age was
44 years (range, 26–68 years), which included 37 male
and 15 female patients. The patients’ characteristics are
summarized in Table 1. The study population included
29 patients with tumor stage II, 14 patients with tumor
stage III and 9 patients had stage IV. Of the 52 total pa-
tients, the distribution of T stages was 6 (11.5%) stage T1,
23 (44.2%) stage T2, 14 (26.9%) stage T3 and 9 (17.3%)Table 1 Patient characteristics
Characteristics Number Percentile (%)








Clinical stage II 29 55.8
III 14 26.9
IV 9 17.3
Neoadjuvant chemotherapy Yes 44 84.6
No 8 15.4
Concurrent chemotherapy Yes 45 86.5
No 7 13.5
Neck boost No 43 58.2
EB boost 9 17.3stage T4. All of the patients enrolled in this study were N1
stage.
Fourteen patients in stage III and 8 patients in stage IV
received neoadjuvant chemotherapy. Concurrent chemo-
therapy was implemented in 45 patients, while others re-
fused concurrent chemotherapy for economic reasons or
toxic effects such as emesis. Twenty-seven (51.9%) pa-
tients with no enlarged left upper cervical lymph node did
not accept left neck lymph node irradiation of levels IV
and VB. Additionally, 25 (48.1%) of the patients with no
enlarged right upper cervical lymph node did not accept
right neck lymph node irradiation of levels IV and VB.
Survival and failure
The median follow-up time for the entire group was 29
months (range, 12–52 months). Table 2 summarizes the
failure pattern. Among all of the patients, 3 patients who
had residual nasopharyngeal disease and 9 patients who
had residual cervical lymph node disease received an
external beam boost. At the time of this analysis, only 1
patient experienced nodal recurrence in level II, 1 pa-
tient developed primary area disease recurrence and
distant metastasis occurred in 3 patients. Additionally,
none of the patients experienced an out-of-radiation-
field nodal disease recurrence. Three patients died, and
the major failure pattern was distant metastasis: 1 pa-
tient developed nasopharyngeal disease recurrence and
was treated with external beam boost, though the patient
eventually died from distant lung metastasis after salvage
chemotherapy; one patient experienced hepatic metasta-
sis; another patient suffered in-field neck disease recur-
rence and received neck lymphadenectomy. The 3-year
OS rate of the whole cohort was 92.2%, and the 4-year
PFS, LFS, NFS and DMFS were 94.1%, 94.3%, 98% and
94.1%, respectively (Figure 1).
Late toxicities
With the IMRT technique, the late toxicities observed
were generally mild or moderate; the most commonTable 2 Failure patterns and sites of distant metastasis
Failure Frequency Percentile (%)
Local recurrence 1 1.9
Local & nodal recurrence 0 0









Figure 1 Disease progression and overall survival in patients with stage N1 nasopharyngeal carcinoma treated with omitting
irradiation to the contralateral lower neck. (A) overall survival (OS), (B) progress-free survival (PFS), (C) local failure-free survival (LFS), (D)
distant metastasis-free survival(DMFS), and (F) nodal recurrence-free survival (NFS).
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(13.5%) patients had grade 1–2 xerostomia, 9 (17.3%)
had subcutaneous fibrosis and 6 (11.5%) had tinnitus.
None of the patients suffered from cranial neuropathy,
trismus or brain damage, and no grade III-IV late toxic-
ities were observed.
Univariate and multivariate analyses
The data used for univariate and multivariate analyses
included the patients’ age, sex, T staging, energy beam
boost and chemotherapy, and possible prognostic factors
are presented in Table 3. Univariate analyses revealed
that that T classification was the only significant prog-
nostic factor for overall survival, and age significantly
influenced the PFS. Additionally, there was a tendency
toward decreased local control with increased T staging,
although the P value did not reach statistical signifi-
cance. This result may be due to the small sample size
in this series. The age (>44 years) was also a predictor
for OS in the multivariate analysis (P=0.045, hazard ratio
[HR] 1.176, 95% confidence interval [CI] 1.003-1.378).However, the local or nodal recurrence was not affected
by any other prognosticator that we studied, such as age,
sex, T classification or chemotherapy.
Discussion
Radiation therapy is a mainstay in the treatment of NPC.
Irradiation from the bilateral upper cervical lymph node
areas down to the supraclavicular fossa has long been
the standard treatment model for radiation therapy of
NPC [17-19] because of the abundant supply of lymph-
atic networks in the nasopharynx. This methodology is
based on reports by Nq WT et al. and Tang L et al. who
had confirmed cervical lymph adenopathy in more than
85% patients with NPC, while approximately 50% patients
demonstrated bilateral cervical lymph node metastasis
[6,20,21] in an occult cervical lymph node metastatic
model. The limitations of previous studies include the
following: first, due to the poor imaging techniques, most
patients were staged by clinical palpation; and second,
outdated radiation techniques led to an inhomogeneous
dose in the target, which may cause poor regional control.
Table 3 Univariate analysis of prognostic factors
3-y OS 3-y LFS 3-y NFS 3-y DFFS 3-y PFS
% P % P % P % P % P
Gender 0.777 0.379 0.584 0.814 0.908
M 92.1 92.2 97.2 94.5 91.8
F 92.3 100 100 93.3 93.3
Age 0.069 0.125 0.327 0.079 0.040
≧44 83.6 87.4 96.0 88.3 84.4
<44 100 100 100 100 100
T stage 0.037 0.078 0.268 0.429 0.199
T1-T2 100 100 100 96.6 96.6
T3-T4 80.8 85.0 95.5 91.1 86.7
Chemotherapy 0.471 0.531 0.709 0.497 0.428
Yes 90.8 93.1 97.7 93.2 91.0
No 100 100 100 100 100
Boost 0.711 0.366 0.079 0.330 0.969
Yes 83.3 83.3 91.7 100 91.7
No 94.6 97.5 100 92.3 92.5
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local and regional control and with OS rates of approxi-
mately 85%, 90% and 80% with or without chemotherapy
[22-25]. Several articles subsequently addressed the
probability that skip metastasis in the cervical nodal
areas was extremely low, with ranges between 0.2% and
7.9%; moreover, cervical lymph node metastases in NPC
always follow an orderly spreading pattern [6,20,26-28].
Additionally, the most common regions for cervical
lymph node metastasis were the RLNs and level II at
frequencies of 69% and 70%, respectively. However, only
11% of patients developed cervical lymph node metasta-
sis in level IV [29]. Subsequently, Su SF et al. [30]
reported that in NPC patients with N0 disease, there
was no regional disease recurrence even if radiation was
applied to the primary tumor and upper neck nodal
areas only, while the 5-year regional control, local con-
trol and OS rates were 95.6%, 93.4% and 89.8%. More-
over, Yunsheng Gao et al. [7] and Xiaomin Ou et al. [8]
demonstrated that elective neck irradiation to levels II,
III and VA was not only suitable for patients with N0
disease but also appropriate for patients with only RLN
metastasis; with this treatment, the out-of-field recur-
rence rates were 0.2% and 0.84%, respectively. Addition-
ally, the authors described high local control rates of
88.6% and 81.4% respectively, while the OS rates were
84.2% and 93.6%.
In consideration of the previous results, it is reason-
able to challenge the necessity of whole bilateral cervical
lymph node area irradiation. This is the first time our re-
search focused on the cervical irradiation range in N1
patients with unilateral cervical lymph node metastasis.The assumption underlying the design of our trial was
that irradiation only to the bilateral upper cervical nodal
areas and unilateral lower neck without prophylactic
treatment to the other side of the lower neck in unilat-
eral cervical metastasis is feasible. Our analysis showed
excellent local and regional tumor control for N1 NPC
patients with only unilateral upper cervical lymph node
metastasis who were treated with radiotherapy to the bi-
lateral upper cervical nodal areas (levels II, III and VA)
and the unilateral lower neck, where ipsilateral upper neck
lymph node metastasis existed (levels IV and VB down to
supraclavicular fossa) and for patients with primary dis-
ease. The 3-year overall survival and local control rates
were 92.2% and 94.3%. More importantly, only one patient
experienced nodal disease recurrence in the irradiation
field, and no patients experienced out-of-field recurrence.
Furthermore, the 3-year NFS rate was 98%. Our results
were similar to Gao et al. [7] and Chen et al. [31], who also
reported low nodal recurrence rates of 3.4% and 3.3%.
Univariate analyses suggest that T classification was the
only significant prognostic factor for predicting overall
survival and that age was a predictor of PFS. Moreover, we
observed a tendency for decreased local tumor control
with increasing T classification; however, the P value did
not indicate statistical significance, which we attributed to
the small sample size. Multivariate analysis indicated that
elective neck irradiation was not a significant predictor for
local or nodal control. However old age was an independ-
ent predictor for OS; this result corresponded with previ-
ous reports [8,32]. Here, we concluded that elective neck
irradiation was not inferior to irradiation of the entire bi-
lateral cervical lymph node area.
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cervical lymph node metastasis staging for NPC is cru-
cial. Previously, the traditional CT scan was a common
method for NPC staging and for designing therapeutic
strategies. Today, however, the multi-slice spiral CT scan,
which has excellent resolution, and MRI have become the
mainstream methods and have replaced the traditional
CT scan. MRI, with its higher sensitivity, is superior to CT
scans for detecting tumor extensions, soft-tissues and
critical structures [33,34]. Here, we combined contrast-
enhanced CT and MRI, and we estimated primary tumor
and cervical lymph node metastasis accurately, which
provides more potential for implementing precise radio-
therapy. In addition to the new techniques for oncologic
imaging, IMRT plays a vital role in tumor control. Lee N
et al. confirmed that through delivery of high doses up to
the target volume without affecting normal structures,
IMRT may provide better tumor control [35]. Addition-
ally, Ou et al. reported that IMRT displayed the capacity
to improve regional control [8]. For NPC, the doses for
potential risk sites, such as subclinical cervical areas, were
vital for regional control; the consensus opinion is that a
dose of 50–60 Gy is necessary [36]. In the Ou et al. study
[8], the dose for the upper neck was the independent
prognostic factor of NFS in patients with only RLN metas-
tasis. The authors regarded upper-neck lymph areas as po-
tential risk sites and treated them with a relatively higher
dose [8]. A possible explanation for these observations
was that once the unilateral upper neck developed lymph
node metastases, the risk of regional recurrence and me-
tastasis of the contralateral upper neck area and ipsilateral
lower neck area was higher; therefore, an adequate dose
for these areas was crucial. In our study, we directed a
relatively higher dose (60 Gy) to bilateral upper cervical
nodal areas and a moderate dose (54 Gy) to the unilateral
lower neck with lymph node metastasis exists in the ipsi-
lateral upper . The combination of CT and MRI scans was
useful in planning treatments and allowed the accurate
image definition of tumor tissues. The new IMRT tech-
nique provided a better dose distribution, which may
contribute to regional tumor control. Based on the
above results for remarkable nodal control and no out-
of-field disease recurrence, irradiation to the bilateral
upper cervical nodal areas and unilateral lower neck
without prophylactic treatment to the contralateral
lower neck in patients with unilateral cervical metastasis
was appropriate.
The aims of IMRT were to optimize the dose for the
target and to reduce the dose received by normal tissue.
The consensus accepted doses for these potential risk
sites ranged from 50 Gy to 60 Gy [4,23]. However, the ir-
radiation field of the lower neck usually encompasses
the apex of the double-lung, part of trachea, the thyroid
gland, muscle and skin. Although the tolerance doses forthe trachea, thyroid gland, muscle and skin usually ex-
ceed the doses for potential risk sites, the apex of the
double-lung usually has a dose that exceeds the toler-
ance and could be adversely affected. Even in muscle,
which was considered to tolerate a higher radiation dose,
higher dosages have been reported to be related to per-
ipheral neuropathy and, subsequently, decreased quality
of life after irradiation treatment [37]. Although our
study lacked a control group, our data demonstrated
that the rates of certain late toxicities, including skin
dystrophy, subcutaneous fibrosis, cranial neuropathy
and trismus, were low. However, because of the short
follow-up time, various late toxicities, such as temporal
lobe necrosis, hypothyroidism, brachial plexopathy and
hypo-pituitarism, could not be observed sufficiently.
In conclusion, in terms of excellent regional control
and the lack of out-of-field disease recurrence, our pro-
spective study demonstrated that elective irradiation to
bilateral levels of II, III and VA and unilateral levels of
IV and VB, omitted the contralateral lower neck in a
proportion of patients with N1 stage tumors was safe
and practicable.
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